Brief: FDA Approves Urogen Pharma's Jelmyto To Treat Adults With Low-Grade Upper Tract Urothelial Cancer
15/04/2020 19:18
April 15 (Reuters) - FDA:
* FDA GRANTS APPROVAL FOR JELMYTO FOR TREATMENT OF ADULT
PATIENTS
WITH LOW-GRADE UPPER TRACT UROTHELIAL CANCER TO UROGEN PHARMA -
FDA WEBSITE
Source text: (https://bit.ly/2RGlJ1y)
((reuters.briefs@thomsonreuters.com;))
Recent news on UroGen Pharma
See all newsBrief: Urogen Submits NDA For Ugn-103, An Investigational Treatment Of Recurrent Lg-Ir-Nmibc
Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
Brief: Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri
Brief: Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Urogen Announces Refinanced Term Loan Agreement With Pharmakon Advisors